Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunic, Inc. (IMUX : NSDQ)

• Company Description    Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $5.77 Daily Weekly Monthly 20 Day Moving Average: 346,261 shares Shares Outstanding: 30.54 (millions) Market Capitalization: $176.22 (millions) Beta: 1.99 52 Week High: $15.12 52 Week Low: $4.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.03% -20.07% 12 Week -46.18% -40.83% Year To Date -39.71% -30.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 AVENUE SUITE 200 - NEW YORK,NY 10036 USA ph: 332-255-9818 fax: 858-673-6843 jessica.breu@immunic.de http://www.immunic-therapeutics.com

• General Corporate Information    Officers Daniel Vitt - President;Chief Executive Officer;Director Duane D. Nash - Executive Chairman Glenn Whaley - Principal Financial and Accounting Officer Tamar Howson - Director Joerg Neermann - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 4525EP101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 30.54 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.99 Market Capitalization: $176.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 54.60% vs. Previous Quarter: 8.64% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -59.64 12/31/21 - -70.05 09/30/21 - -58.97 ROA 03/31/22 - -54.46 12/31/21 - -63.38 09/30/21 - -53.90 Current Ratio 03/31/22 - 10.11 12/31/21 - 9.21 09/30/21 - 11.57 Quick Ratio 03/31/22 - 10.11 12/31/21 - 9.21 09/30/21 - 11.57 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.52 12/31/21 - 4.84 09/30/21 - 5.54 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©